Ken Fisher is one of the most well-known hedge fund executives in the world. He is the CEO of Fisher Asset Management, a $178 billion hedge fund. According to SEC records, the company’s portfolio is among the largest in the world and in the United States. Between 2014 and 2020, Fisher Asset Management was routinely ranked among the top hundred hedge funds in the United States. In Europe, the fund has won various honors, including one of Cash Online’s Best Employer In The Financial Sector award for 2015.
Insider Monkey highlights Fisher Asset Management’s top biotechnology stock picks. Julian Baker and Felix Baker’s Baker Bros Advisors own 12 million shares worth $176 million in BioCryst Pharmaceuticals, Inc. The company’s fourth-quarter statistics indicated revenue of $47 million and non-GAAP earnings per share of -$0.40. Medpace Holdings, Inc. is a company that provides drug and medical development services based on scientific research. According to Insider Monkey’s survey of 924 hedge funds, 26 have interests in the company. Bio-Rad Laboratories, Inc. is a company that specializes in life science research and diagnostic devices. It creates reagents and equipment for use by healthcare companies, particularly biotechnology enterprises. West Pharmaceutical Services, Inc. reported revenue of $730 million and non-GAAP earnings per share of $2.04, both of which exceeded analyst expectations. In January 2022, the company formed a relationship with Corning, a well-known glass manufacturer. For more details, click Ten Biotechnology Stocks To Buy According To Ken Fisher’s Fisher Asset Management.
